{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:59:58Z","timestamp":1780394398841,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:p>Dupilumab demonstrated efficacy with an acceptable safety profile in two randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group, phase III trials in adolescents (12\u201317\u00a0years; LIBERTY AD ADOL) and children (6\u201311\u00a0years; LIBERTY AD PEDS) with atopic dermatitis (AD) treated for 16\u00a0weeks. Here, we present the pharmacokinetic profiles and exposure\u2010response (E\u2010R) relationships of dupilumab that guided the posology in these populations. A total of 251 adolescent patients with moderate\u2010to\u2010severe AD were randomized to subcutaneous dupilumab monotherapy every 2\u00a0weeks (q2w; 200\u00a0mg q2w, baseline weight &lt;\u00a060\u00a0kg; 300\u00a0mg q2w, \u2265\u00a060\u00a0kg), dupilumab 300\u00a0mg every 4\u00a0weeks (q4w; non\u2010weight tiered), or placebo; 367 children with severe AD were randomized to dupilumab q2w (100\u00a0mg q2w, baseline weight &lt;\u00a030\u00a0kg; 200\u00a0mg q2w, \u2265\u00a030\u00a0kg), dupilumab 300\u00a0mg q4w, or placebo. Children received concomitant topical corticosteroids in addition to dupilumab, and loading doses were administered at the start of therapy. Mean dupilumab trough concentrations at week 16 for weight subcategories in each dosing regimen were compared with adult exposures for the approved dupilumab 300\u00a0mg q2w regimen. Positive E\u2010R relationships were demonstrated between dupilumab trough concentrations and AD outcome measures across patient populations and regimens; no relationship was observed with treatment\u2010emergent conjunctivitis. Based on these analyses, a weight\u2010tiered posology was proposed for adolescents (200\/300\u00a0mg q2w in patients 30\u2013&lt;\u00a060\u00a0kg\/\u2265\u00a060\u00a0kg) and children (300\u00a0mg q4w in patients 15\u2013&lt;\u00a030\u00a0kg, 200\u00a0mg q2w in patients 30\u2013&lt;\u00a060\u00a0kg) with moderate\u2010to\u2010severe AD.<\/jats:p>","DOI":"10.1002\/cpt.2366","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T19:00:28Z","timestamp":1626462028000},"page":"1318-1328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis"],"prefix":"10.1111","volume":"110","author":[{"given":"Mohamed A.","family":"Kamal","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Kovalenko","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Kosloski","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Rajadhyaksha","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Ha","family":"Lai","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanaja","family":"Kanamaluru","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Xu","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Sun","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Oregon Health and Science University Portland Oregon USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy S.","family":"Paller","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine Chicago Illinois USA"},{"name":"Ann and Robert H. Lurie Children\u2019s Hospital Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine C.","family":"Siegfried","sequence":"additional","affiliation":[{"name":"Saint Louis University St. Louis Missouri USA"},{"name":"Cardinal Glennon Children\u2019s Hospital St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Bansal","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidal","family":"Al\u2010Huniti","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6282-1670","authenticated-orcid":false,"given":"John D.","family":"Davis","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc. Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13320"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.251"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.10.009"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13599"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04636.x"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-019-00342-w"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15928"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_11_13_1","unstructured":"U.S. Food and Drug Administration. Dupixent (dupilumab).Highlights of prescribing information<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761055s020lbl.pdf> (2021). Accessed April 7 2021."},{"key":"e_1_2_11_14_1","unstructured":"European Medicines Agency.Dupixent (dupilumab). Summary of product characteristics<https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/dupixent\u2010epar\u2010product\u2010information_en.pdf> (2021). Accessed January 29 2021."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16156"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.3336"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.054"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.062"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0625.2001.100102.x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17744"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1058"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12136"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.780"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.986"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869"},{"key":"e_1_2_11_28_1","unstructured":"U.S. Food and Drug Administration.Draft guidance for industry: general clinical pharmacology considerations for pediatric studies for drugs and biological products<http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM425885.pdf> (2014). Accessed January 29 2021."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2366","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:38:45Z","timestamp":1699364325000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/cpt.2366"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2366","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"2021-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}